New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

Farxiga OK’d for Kids; Semaglutide Price Hearing; Maintaining GLP-1 Weight Loss

The FDA approved dapagliflozin (Farxiga) for glycemic control in children ages 10 years and older with type 2 diabetes, based on results from the phase

June 19, 2024

Stock Market Review 28AUG23 #shorts

August 29, 2023

Opinion | Perception Is Reality: NIH’s Role on Drug Pricing and Data Transparency

Jeremy Faust is editor-in-chief of , an emergency medicine physician at Brigham and Women’s Hospital in Boston, and a public health researcher. He is author

April 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.